Intratumoral Combinatorial Administration of CD1c (BDCA-1)⁺ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in re-licensing antitumor cytotoxic T lymphocytes. IT injection of the IgG₁ monoclonal antibodies ipilimumab and avelumab may induce antibody-dependent cellular cytotoxicity, thereby enhancing the release of tumor antig...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2020-11-01
Serier:	Vaccines
Fag:	cancer immunotherapy dendritic cells intratumoral myeloid dendritic cells conventional dendritic cells immune checkpoint inhibitors
Online adgang:	https://www.mdpi.com/2076-393X/8/4/670
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!